Lever
Lifestyle
- Regular weight-bearing exercise
- Smoking cessation
- Moderate alcohol consumption
Blutwerte · Marker
CTX
C-terminal Telopeptide · Beta-CrossLaps · CTX · Bone Resorption Marker
Knochen & MineralogieNüchtern erforderlichZeitabhängig
- Einheit:
- ng/mL
- Abbreviation
- CTX / b-CTX
CTX quantifies the amount of C-terminal telopeptide of type I collagen, a marker of bone resorption.
Reference Ranges
Reference
0.1–0.6ng/mL
0.1
0.6
LowNormalHigh
Reference
Unit · ng/mLLevels may vary with age, sex, and renal function. Morning fasting samples are recommended.
Overview
Übersicht
C-terminal telopeptide (CTX), also known as Beta-CrossLaps, is a biochemical marker of bone resorption. It is a fragment of type I collagen released into the bloodstream during bone degradation. CTX is primarily used to assess the rate of bone turnover, which is crucial in understanding bone health, particularly in conditions like osteoporosis. Researchers have found that CTX levels correlate with bone resorption rates, making it a valuable tool in monitoring the effectiveness of osteoporosis treatments and predicting fracture risk. Elevated CTX levels are associated with increased bone resorption, which can lead to decreased bone density and higher fracture risk, especially in postmenopausal women. CTX is clinically significant in diagnosing and managing osteoporosis, as well as in evaluating the effectiveness of anti-resorptive therapies such as bisphosphonates and denosumab. In the context of athletic performance and biohacking, CTX can provide insights into bone health and the impact of various interventions on bone turnover. However, its use in these areas is less established compared to its role in managing osteoporosis. Researchers observed that CTX levels can be influenced by several factors, including circadian rhythms and renal function. It is recommended to measure CTX levels in the morning after an overnight fast to minimize variability. Additionally, CTX levels may be elevated in individuals with chronic kidney disease due to impaired renal clearance, which can confound the interpretation of results. Therefore, careful consideration of these factors is essential when using CTX as a biomarker for bone health assessment.
Klinische Bedeutung
Elevated CTX levels indicate increased bone resorption, often seen in osteoporosis and other conditions with high bone turnover. Reduced CTX levels suggest decreased bone resorption, which may occur with effective anti-resorptive therapy.
Dynamics
Trend Interpretation
Rising Values
Progressively rising CTX values suggest increased bone resorption, potentially indicating worsening osteoporosis. Re-test in 3 months if elevated.
Falling Values
Progressively falling CTX values indicate reduced bone resorption, often seen with effective treatment.
Re-test Interval
3-6 months for monitoring treatment efficacy.
Etiology
Causes — High & Low
Cause
Elevated Levels
- Osteoporosis
- Hyperparathyroidism
- Paget's disease
- Chronic kidney disease
- Prolonged immobilization
Cause
Low Levels
- Effective anti-resorptive therapy
- Hypoparathyroidism
- Low bone turnover states
- Malnutrition
Protocol
How to Optimize
Lever
Nutrition
- Adequate calcium intake
- Vitamin D-rich foods
Lever
Supplementation
- Calcium
- Vitamin D
Note:
Consult a healthcare provider before starting any supplementation, especially if on medication for bone health.
Testing Guidelines
🍽️Fasting Required
🕐Time-Sensitive
CTX levels show diurnal variation; morning fasting samples are recommended.
Testing Frequency
Every 3-6 months for osteoporosis management.
Interfering Factors
- Recent intense exercise
- Chronic kidney disease
- Non-fasting state
Related Peptides & Hormones
Parathyroid Hormone
hormone or peptideMay affect
Open Research Questions
Current research suggests that the interaction of β-CTX-I with other fracture risk factors remains insufficiently studied, limiting its incorporation into fracture risk algorithms. Researchers have not yet established standardized reference ranges for β-CTX-I in populations with advanced chronic kidney disease, where its levels may be affected by renal function. Additionally, clinical questions remain unanswered regarding the optimal targets for β-CTX-I in monitoring treatment response and fracture risk reduction in diverse patient populations.
22 Research Publications
1,964
Total Citations
11
Human/RCT
11.6
Avg. Influence
2023
Latest
Sort
Filter
01Top
#01
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
ReviewInfluence63.0
1119
Researchers found that bone turnover markers, including serum procollagen type I N propeptide (s-PINP) and serum C-terminal telopeptide of type I collagen (s-CTX), are valuable for predicting fracture risk and monitoring osteoporosis treatment. They emphasized the need for standardized assays to enhance the reliability of these markers in clinical practice.
02Top
#02
The spread of CTX-M-type extended-spectrum beta-lactamases.
ReviewInfluence13.0
194
Researchers discussed the rapid global spread of CTX-M-type extended-spectrum beta-lactamases among Enterobacteriaceae. They highlighted the implications for laboratory detection and the emergence of variants with enhanced resistance, which is changing the landscape of antibiotic resistance.
03Top
#03
Osteoarthritis Year in Review 2016: biomarkers (biochemical markers).
Mobasheri A, et al. · Osteoarthritis and cartilage · 2017
ReviewInfluence3.0
157
This review summarized advancements in biomarker research related to osteoarthritis. Researchers identified new biomarkers and technologies for measuring existing ones, but noted that significant challenges remain in identifying early biomarkers for osteoarthritis.
Key findings
- 01Researchers observed the identification of new biomarkers like ADAMTS-4 and CCL3 for knee osteoarthritis.
- 02They noted advancements in measurement technologies, including a novel magnetic nanoparticle-based method.
- 03Researchers highlighted the publication of new guidelines for using biomarkers in clinical trials, which could enhance future studies.
04
#04
Calcium and Bone Metabolism Indices.
ReviewInfluence5.0
128
Researchers observed that calcium and phosphate homeostasis is tightly regulated, with bone turnover markers like serum N-terminal propeptide of type I procollagen (P1NP) and C-terminal telopeptide (CTX) potentially useful for predicting fracture risk. The study calls for standardization of sample collection protocols to improve the clinical utility of these markers.
05
#05
Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis.
HumanInfluence6.0
104
This study reviewed the diagnosis and treatment outcomes in patients with cerebrotendinous xanthomatosis (CTX). Researchers found that treatment significantly reduced plasma cholestanol levels and improved symptoms in many patients. The study suggests that early diagnosis and treatment can prevent complications associated with CTX.
06
#06
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
HumanInfluence7.0
86
Researchers observed that treatment with zoledronate after discontinuation of denosumab in postmenopausal individuals did not prevent increased bone turnover or significant bone loss over two years. However, levels of p-cross-linked C-terminal telopeptide (p-CTX) remained within the reference range during the second year. The study indicates that monitoring CTX levels is crucial for assessing bone health post-treatment.
07
#07
Rapid emergence of extensively drug-resistant Shigella sonnei in France.
HumanInfluence3.0
60
This study reported on the rapid emergence of extensively drug-resistant Shigella sonnei in France. Researchers documented the increasing resistance to multiple antibiotics and highlighted the importance of laboratory surveillance for effective public health responses. The findings raise concerns about the implications of these resistant strains on treatment options.
08
#08
An update on biomarkers in axial spondyloarthritis.
Prajzlerová Klára, et al. · Autoimmunity reviews · 2016
ReviewInfluence1.0
53
This review focused on biomarkers for axial spondyloarthritis, noting that while HLA-B27 is a key genetic marker, other biomarkers like CTX-II may help predict structural progression. Researchers emphasized the need for further validation of these biomarkers in larger studies before they can be routinely used in clinical practice.
Key findings
- 01HLA-B27 is currently the best genetic biomarker for diagnosing axial spondyloarthritis.
- 02CRP is the most effective circulating measure for assessing disease activity and predicting progression.
- 03New biomarkers, such as calprotectin, may help monitor therapeutic responses but require further validation.
09
#09
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
HumanInfluence3.0
37
This study examined the relationship between tumor monocyte content (TMC) and outcomes in patients with inoperable esophageal adenocarcinoma receiving immunochemotherapy. Researchers found that high TMC predicted better overall survival and response to treatment. Additionally, they identified a novel T cell inflammation signature correlated with tumor shrinkage during therapy.
10
#10
Expression and diagnostic significance of integrin beta-2 in synovial fluid of patients with osteoarthritis.
Human
9
This study investigated the expression of integrin beta-2 in the synovial fluid of osteoarthritis patients. Researchers found that elevated levels of integrin beta-2 correlate with increased β-CTX levels, suggesting its potential as a biomarker for osteoarthritis severity. The study indicates that integrin beta-2 may assist in diagnosing osteoarthritis.
Clinical Trials (1)
1
Total Trials
12
Total Enrolled
The Effect of Glucose on Bone - Direct og Indirect?
NCT02213276UNKNOWN
Sponsor
University of Aarhus
Enrollment
12
Started
2014
Primary outcome
The resorptive bone marker S-CTX.
Glucose InfusionBone MarkersInflammatory Markers
Publication Trend
Research publications about CTX over time
8totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer